Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download proteomics for human neuropsychiatric diseases/biomarkers for
Document related concepts
no text concepts found
Transcript
PROTEOMICS FOR HUMAN NEUROPSYCHIATRIC DISEASES/BIOMARKERS FOR NEUROPSYCHIATRIC DISORDER NOVEMBER 2-3, 2006 MARRIOTT ANNAPOLIS WATERFRONT HOTEL 80 COMPROMISE STREET ANNAPOLIS, MD 21401 THE IMPORTANCE OF BIOMARKERS FOR THE STANLEY MEDICAL RESEARCH INSTITUTE Michael Knable, The Stanley Medical Research Institute WHAT WE KNOW AND DON’T KNOW ABOUT SCHIZOPHRENIA AND BIPOLAR DISORDER E. Fuller Torrey, The Stanley Medical Research Institute CHARACTERIZATION OF POPULATIONS AND SAMPLE COLLECTIONS Maree Webster, The Stanley Medical Research Institute THE STANLEY BRAIN GENOMICS DATABASE Michael Elashoff, The Stanley Medical Research Institute STUDIES OF INDIVIDUALS WITH RECENT ONSET AND ESTABLISHED SCHIZOPHRENIA OR BIPOLAR DISORDER Faith Dickerson, Sheppard Pratt Health System TESTING GENE-ENVIRONMENT INTERACTIONS IN SCHIZOPHRENIA GENESIS Vishwajit Nimgaonkar, Western Psychiatric Institute & Clinic INDIVIDUALS WITH FIRST EPISODE PSYCHOSIS Marcus Leweke, University of Cologne THE MILITARY AS A SERO-EPIDEMIOLOGIC LABORATORY: THE MNOPP EXPERIENCE David Niebuhr, Walter Reed Army Institute of Research PRENATAL COHORTS, BANKED SERUM AND THE ORIGINS OF SCHIZOPHRENIA: SCIENTIIFIC BREAKTHROUGH OR BUSINESS AS USUAL? Stephen Buka, Brown University POPULATION BASED APPROACHES TO THE IDENTIFICATION OF BIOMARKERS AND PREDICTION OF DISEASE Preban Mortensen, National Centre for Register-based Research, University of Aarhus, Denmark DISEASE BIOMARKERS IN FIRST-ONSET SCHIZOPHRENIA Sabine Bahn, University of Cambridge CSF BIOMARKER DISCOVERY FOR SCHIZOPHRENIA USING PROTEOMIC AND METABOLIC APPROACHES Jeffrey Huang, University of Cambridge CONVERGENCE OF BLOOD AND BRAIN GENE EXPRESSION IN SCHIZOPHRENIA AND BIPOLAR DISORDER Gursharan Chana, University of California San Diego BIOMARKER PATTERNING WITH MAP TECHNOLOGY TO FACILITATE NOVEL DIAGNOSTIC AND DRUG DEVELOPMENT Ralph McDade, Rules Based Medicine FINDING SUBTYPES IN PSYCHOSIS USING GENE EXPRESSION MICROARRAY STUDIES Kwang Ho Choi, The Stanley Medical Research Institute EXPOSURE TO INFECTIOUS AGENTS AND INFLAMMATORY RESPONSE IN INDIVIDUALS WITH BIPOLAR DISORDER Faith Dickerson, Sheppard Pratt Health System META-ANALYSIS OF 12 GENOMIC STUDIES IN BIPOLAR DISORDER Michael Elashoff, The Stanley Medical Research Institute COMPARISON OF SERUM PREPARATION AND OPTIMIZATION METHODS FOR SELDITOF-MS Bogdana Krivogorsky, Johns Hopkins University, Stanley Division PATTERNS OF KYNURENINE PATHWAY ACTIVATION AS BIOMARKERS FOR SCHIZOPHRENIA AND BIPOLAR DISORDER Christine Miller, Johns Hopkins University, Stanley Division A CASE-CONTROL STUDY OF ANTIBODIES TO TOXOPLASMA GONDII AND RISK OF SCHIZOPHRENIA AMONG MILITARY PERSONNEL David Niebuhr, Walter Reed Army Institute of Research CHRONOTYPES AS BIOMARKERS FOR BIPOLAR DISORDER? Vishwajit Nimgaonkar, Western Psychiatric Institute and Clinic/UPMC POLYMORPHISMS IN THE HOMEOBOX GENE OTX2 IN SCHIZOPHRENIA AND BIPOLAR DISORDER Sarven Sabunciyan, Johns Hopkins University, Stanley Division METABOLIC PROFILING OF SERUM FROM SCHIZOPHRENIA PATIENTS: IDENTIFICATION OF POENTIAL DISEASE BIOMARKERS Emanual Schwarz, University of Cambridge RIC-3 CONGRUENCE WITH NICOTINIC ACETYLCHOLINE RECEPTOR SUBUNIT EXPRESSION IS ALTERED IN BIPOLAR DISORDER Emily Severance, Johns Hopkins University, Stanley Division IDENTIFICATION OF PROTEIN ALTERATIONS IN SCHIZPHRENIA: CHANGES IN COFORMATION AND OXIDATION STATE Consuelo Walss-Bass, University of Texas Health Science Center LIPIDOMIC MAPPING OF ATYPICAL ANTIPSYCHOTIC EFFECTS IN SCHIZOPHRENIA Rima Kaddurah-Daouk, Duke University Medical Center SEARCHING FOR PROTEIN BIOMARKERS IN SCHIZOPHRENIA Hung-The Kao, Nathan Kline Institute NEUROIMMUNE MARKERS AND SCHIZOPHRENIA: WHY ARE WE STILL IGNORING THEM? Karoly Mirnics, Vanderbilt University THE HUMAN PROTEOME PROJECT N. Leigh Anderson, Plasma Proteome Institute MAKING IT SMALL: PROTEIN MICROARRAYS FOR BIOMARKER DISCOVERY Markus Templin, University of Tuebingen MULTIPLEX SEROLOGY – A TOOL TO LINK SPECIFIC INFECTIONS AND DISEASE Michael Pawlita, German Cancer Research Center QUANTITATIVE PROTEOMICS APPLIED TO BIOMARKER DISCOVERY AND EVALUATION Bruno Domon, Institute for Molecular Systems Biology, Switzerland BIOMARKERS FOR BRAIN DISEASE Lance A. Liotta, George Mason University ENHANCING BIOMARKER QUANTIATION: THE INSTRUMENT QUALIFICATION CYCLE Fiona Plows, Ciphergen Biosystems A NEW MR AND PROTEOMIC DETECTION METHODS FOR BRAIN MICROHEMORRHAGES – A CAUSE FOR SPORADIC LATE-ONSET DEMENTIA Wolff Kirsch, Loma Linda University
